AANS Neurosurgeon | Volume 27, Number 1, 2018

Advertisement

Discovery May Lead to a Treatment to Slow Parkinson's Disease

Interaction between a mutant gene and alpha synuclein leads to hallmark Parkinson’s pathologies 

In this study, researchers were able to see that LRRK2, a mutant kinase enzyme that is the most common genetic cause for Parkinson’s disease, can cause the buildup of inclusions in neurons. These inclusions are one of the main pathologies seen in patients with Parkinson’s disease. New drugs that are currently being developed for clinical use would inhibit the buildup of inclusions stopping the aggregated alpha synuclein protein which would slow the progression of the disease. To read more, click here.

Calendar/Courses

Second International Brain Mapping Course
April 26-27, 2018; New Orleans

Surgical Approaches to Skull Base
April 26-28, 2018; St. Louis, MO

2018 AANS Annual Scientific Meeting
April 28-May 2, 2018; New Orleans

Comments are closed.